HIV/AIDS Flashcards

1
Q

Global HIV/AIDS Epidemic

A
  • An estimated 33.3 million people are living with HIV worldwide as of 2009
  • 30.8 million adults
  • 15.9 million women
  • 2.5 million children under 15 years of age
  • Approximately 2.6 million new HIV infections occurred in 2009
  • Estimated 1.8 million deaths occurred in 2009 due to AIDS
  • People living longer with HIV/AIDS may play a role in increasing the # of + persons
  • Vertical transmission = from mother to baby
  • 13-18 yo increasing
  • An estimated 33.4 million people were living with HIV in 2008—
    - Women: 15.7 million
  • Men: 15.6 million
  • Children: 2.1 million
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Awareness of HIV Status in the US

A
  • HIV estimated prevalence: 1,056,400 - 1,156,400
  • Undiagnosed: 232,700
  • Estimated newannual infections (2006): 56,300
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HIV Transmission

A

HIV is transmitted through contact with contaminated body fluids, such as:

  • Blood and blood products
  • Semen
  • Vaginal secretion
  • HIV is not transmitted through other body fluids such as saliva, tears, or sweat
  • HIV is not transmitted via air, water, or insects (including mosquitoes)
  • Saliva doesnt have a lot of the virus, if they have open sores then maybe
  • Post exposure prophylaxis – have around 72 hrs., but the sooner the better, used also for those with sexual assault
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Modes of Transmission for HIV: Part 1

A
  • Unprotected sexual contact is one of the most common methods of transmitting HIV
  • Unprotected anal intercourse has a higher risk of HIV transmission than unprotected vaginal intercourse
  • Unprotected receptive anal intercourse has a higher risk of HIV transmission than unprotected insertive anal intercourse
  • Unprotected oral intercourse has a much lower risk of HIV transmission than anal or vaginal intercourse

Risk of HIV transmission from sexual contact may also increase with:

  • Multiple sex partners
  • Presence of other sexually transmitted diseases (STDs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Modes of Transmission for HIV: Part 2

A
  • HIV can be transmitted by shared needles
  • In addition to needles, sharing syringes, rinse water, or other equipment used to prepare intravenous drugs can also increase the risk of HIV infection
  • Mothers can transmit HIV to their babies during pregnancy, birth, or breast-feeding
  • Receiving blood transfusions, blood products, or organ/tissue transplants contaminated with HIV
  • While originally an important mode of transmission, this risk is now extremely low in the US due to rigorous testing of the blood supply and donated organs/tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Modes of Transmission for HIV: Part 3

A

Less common modes of HIV transmission include:

  • Occupational exposures such as accidental needle sticks
  • Tattooing or body piercing with unsterile instruments
  • Contact between broken skin, wounds, or mucous membranes and HIV-infected blood or blood-contaminated body fluids, such as in a health care setting

Though unlikely, transmission can also occur in the following situations if blood is present in the mouth of the person infected with HIV (eg, bleeding gums)

  • Person with HIV bites someone else and breaks the skin
  • Open-mouth kissing
  • Person with HIV chews food and then transfers it to someone else (usually a child)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HIV Prevention

A

Health care professionals can counsel patients on ways to prevent transmission of HIV, including:

  • Abstaining from sexual activity or being in a long-term mutually monogamous relationship with an uninfected partner
  • Using latex condoms correctly and consistently
  • Considering male circumcision, which has been shown to reduce the risk of transmission during vaginal sex
  • Not injecting drugs. If the patient is unable to stop injecting drugs, encourage the use of clean needles when injecting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Post-exposure Prophylaxis (PEP)

A
  • When started within 48-72 hours after exposure to HIV and continued for 28 days, antiretroviral therapy is thought to decrease the risk of HIV transmission
  • Exposures can be occupational (eg, health care providers) or behavioral (eg, unprotected sex)
  • The risk of infection from exposure to HIV should be considered and weighed against the possible toxicities associated with different PEP regimens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PREP

A

-The concept of providing antiretroviral therapy, the same that could be used to treat HIV, in hopes of preventing the acquisition of HIV to an uninfected person

Who would be a candidate for PREP?
-in a relationship with someone who is +, pay and play parties (parties where sex acts are done for meth), drug seekers, people who sell their body for goods
Risks?
-bone mass depletion (= fx? Not known yet), kidney function decline
Does it work?
-YES, large studies shown, and when not taken it doesnt work, 95% compliance/adherence
-Gel used in sex workers in Africa doesnt really work

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Purpose of Routine HIV Screening

A
  • HIV infection is consistent with all generally accepted CDC criteria that justify routine screening
  • HIV infection is a serious health condition that can be diagnosed before symptoms develop
  • HIV can be detected by reliable, inexpensive, and noninvasive screening tests
  • The costs of screening are reasonable in relation to the anticipated benefits
  • Infected patients have years of life to gain if treatment is initiated early, before symptoms develop
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CDC Recommendations for Routine HIV Screening in the US: Details

A
  • Routine screening for HIV infection is recommended in people aged 13–64 years in all health care settings*
  • Screening should be voluntary and undertaken only with the patient’s knowledge and understanding of the testing planned
  • All patients initiating treatment for tuberculosis (TB) should be screened routinely for HIV infection
  • All patients seeking treatment for STDs should be screened routinely for HIV during each visit for a new complaint, regardless of whether the patient is known or suspected to have specific behavior risks for HIV infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Types of HIV Tests

A
  • The most common type of HIV screening test uses an enzyme immunoassay [enzyme immunoassay (EIA) or enzyme linked immunosorbant assay (ELISA)] to look for antibodies to HIV
  • Test can use blood, oral fluid, or urine
  • Rapid testing is available, with results in about 20 minutes
  • To make a diagnosis, a positive enzyme immunoassay must be confirmed with Western blot or immunofluorescent assay
  • An RNA (or pro-viral DNA) test detect viral genetic material
  • This test can be used for detecting acute HIV infection and can detect HIV before antibodies are made
  • This test can be used to screen the blood supply
  • P24 antigen/HIV antibody combination testing is approved for detection of acute HIV infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HIV Targets the Immune System

A
  • HIV targets the immune system by specifically infecting CD4 cells
  • Over time, HIV depletes the body of CD4 cells, causing an immune deficiency
  • This immune deficiency leads to increased risk of infections that those with normal immune function would not be susceptible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CDC Clinical Disease Classifications

A
  • Category A: HIV infection without symptoms
  • Category B: symptomatic conditions attributable to HIV infection that don’t meet category C definitions: Examples: thrush, idiopathic thrombocytopenic purpura
  • Category C: clinical conditions attributable to HIV infection or CD4 cell count <14%: Equivalent to a diagnosis of AIDS, Examples: PCP, Kaposi’s sarcoma, wasting
  • Once patient has reached clinical category C, the patient remains in that category even if their clinical condition improves
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HIV and Organ Damage

A

-Although immune deficiency from HIV infection can cause significant morbidity and mortality, the direct effects of the virus itself as well as inflammation associated with HIV can also lead to end-organ damage

Conditions associated with organ damage due to HIV

  • HIV-associated nephropathy (HIVAN)
  • Co-infection with hepatitis B or C
  • Cardiovascular disease
  • Non-AIDS associated malignancies
  • Neurocognitive decline
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Monitoring HIV Infection Using Surrogate Markers

A
  • Two surrogate markers are used routinely to assess patients with HIV infection
  • CD4+ cell count: indicator of immune function
  • HIV-1 RNA or viral load: measure of viremia and treatment response
  • CD4 cell count is the strongest predictor of subsequent disease progression and survival
  • Lower viral loads are associated with improved clinical outcomes
17
Q

Highly Active Antiretroviral Therapy—HAART

A
  • HAART usually consists of at least three drugs to decrease viral replication
  • There are more than 20 approved antiretroviral agents available in 6 mechanistic classes
  • With lower rates of viral replication, fewer CD4 cells are destroyed and immune function can improve
  • A key goal of therapy is suppression of viral load to “undetectable,” meaning, it is below the limit of detection of commercially-available HIV assays (usually 50 copies/mL)
  • A person with “undetectable“ viral load may still have low levels of ongoing viral replication, and therefore can still transmit HIV to others
18
Q

Goals of Antiretroviral Therapy

A
  • Maximally and durably suppress viral load
  • Reduce HIV associated morbidity and mortality and prolong survival
  • Restore and preserve immune function
  • Prevent HIV transmission
  • Improve quality of life
19
Q

Factors Associated with Poor Adherence to Antiretrovirals

A
  • Low levels of literacy
  • Certain age-related challenges (e.g., vision loss, cognitive impairment)
  • Psychosocial issues (e.g., depression, homelessness, lower social support, stressful life events, dementia, or psychosis)
  • Active (but not history of) substance abuse, particularly for patients who have experienced recent relapse
  • Stigma
  • Difficulty with medication taking (e.g., trouble swallowing pills, daily schedule issues)
  • Complex regimens (e.g., pill burden, dosing frequency, food requirements)
  • Adverse drug effects
  • Treatment fatigue
  • Potential for drug resistance when missing doses, w/in 48 will have increased viral load and increased mutations that can be resistance, increases transmissions and can be transmitted to already infected with different strains
20
Q

Why Is Understanding Resistance Important?

A
  • Resistance is a major factor that can limit drug efficacy
  • Resistance testing can help guide selection of appropriate antiretroviral treatment
  • Resistance to one drug may lead to cross-resistance to another drug
  • Resistance can limit therapeutic options
21
Q

Types of Resistance Testing: Genotype

A
  • Genotypic assays sequence viral genes to detect mutations that are known to confer drug resistance
  • Interpretation of test results requires knowledge of the mutations that are selected for and/or affect different antiretroviral drugs
  • Genotypic testing is recommended as the preferred resistance test to guide therapy in antiretroviral- naïve patients and in patients with suboptimal virologic responses or virologic failure while on first or second regimens
22
Q

Types of Resistance Testing: Phenotype

A
  • Phenotypic assays measure the ability of a virus to grow in the presence of different concentrations of each antiretroviral agent
  • Phenotypic assays are more expensive than genotypic assays, and results typically take 2-3 weeks
  • Phenotypic in addition to genotypic testing are generally preferred for persons with known or suspected complex drug resistance mutation patterns, particularly to protease inhibitors
23
Q

Recommendations for Drug Resistance Testing

A

Testing for drug-resistant HIV is recommended for persons with HIV infection:

  • When entering into care, regardless of whether therapy will be initiated immediately or deferred
  • When choosing an initial or subsequent* therapeutic regimen
  • When managing suboptimal virologic response or virologic failure*

-Resistance testing is specifically recommended for all pregnant women at the beginning of pregnancy, prior to initiation of therapy, or for detectable HIV RNA levels while on therapy